Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) has shared an update.
Alligator Bioscience announced that the European Medicines Agency (EMA) has provided positive scientific advice for the Phase 3 trial design of mitazalimab, a treatment for metastatic pancreatic cancer. This endorsement aligns with previous FDA feedback, facilitating a unified global Phase 3 study and advancing mitazalimab towards potential registration as a new treatment option in major territories.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company focused on developing clinical-stage tumor-directed antibody drugs targeting the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive nature of the tumor microenvironment, offering potential benefits for cancer patients across various cancer types. The company is listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.
Average Trading Volume: 245,135
Current Market Cap: SEK146.2M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.